Acute Myocardial Infarction (AMI)
Conditions
Brief summary
Evaluate the clinical application value of the novel radiolabeled TSPO-targeted molecular probe Gallium \[68Ga\]-DOTA-HK-011 for inflammation imaging associated with acute myocardial infarction.
Interventions
None listed
Sponsors
Nanjing First Hospital, Nanjing Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Volunteers, patients, or their legal representatives must sign the informed consent form and be able to cooperate with the PET-MR examination by lying flat for more than 30 minutes and maintaining a stable position. * No gender restrictions; age between 18 and 75 years, inclusive. * Patients must meet the diagnostic criteria for acute myocardial infarction (AMI), such as elevated myocardial enzyme spectrum, dynamic changes in electrocardiogram, or confirmation by coronary angiography. * Patients who are 7 to 10 days post-onset of acute myocardial infarction. * Renal GFR \> 50 ml/min; ERPF \> 280 ml/min; platelet count (PLT) \> 75,000/μL; white blood cells (WBC) \> 3,000/μL; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels less than three times the upper limit of normal.
Exclusion criteria
* Individuals with a history of allergy to similar drugs (drugs with similar chemical or biological components to TSPO), a history of allergies, or currently suffering from allergic diseases. * Use of anti-inflammatory drugs (such as corticosteroids or immunosuppressants) within the last 14 days, which may affect inflammation imaging. * Hemodynamically unstable conditions (such as cardiogenic shock or severe arrhythmias); Recent cerebral hemorrhage or severe bleeding tendency within the last 30 days. * Red blood cell count (RBC) \< 4×10\^12/L, white blood cell count (WBC) \< 3×10\^9/L, hemoglobin less than 110 g/L, platelet count (PLT) \< 75×10\^9/L. * Significant abnormal liver or kidney function, with glomerular filtration rate (GFR) less than 50 ml/min. * Presence of ferromagnetic metals implanted in the body (such as cardiac pacemakers, artificial heart valves, metal stents, etc.). * Claustrophobia or inability to tolerate prolonged examinations. * Presence of severe acute concomitant diseases or severe refractory mental disorders. * Pregnant or breastfeeding women (pregnancy defined as a positive urine pregnancy test). * Patients whose physical condition contraindicates radioactive examinations, such as severe cardiopulmonary insufficiency or other conditions deemed unsuitable by the investigator. * Other circumstances deemed unsuitable for participation in the trial by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUVmax of lesion uptake value | Time Frame: 60min after administration |
Contacts
Primary ContactFeng Wang
Outcome results
None listed